| 11. |
|
|
| 12. |
- Chernitskiy, S. V., et al.
(författare)
-
Neutronic Model Of A Fusion Neutron Source
- 2013
-
Ingår i: Problems of Atomic Science and Technology. - 1562-6016. ; :1, s. 61-63
-
Tidskriftsartikel (refereegranskat)abstract
- The MCNPX numerical code has been used to model a fusion neutron source based on a combined stellarator-mirror trap. Calculation results for the neutron spectrum near the inner wall and radial leakage of neutrons through the mantle surface of the fusion neutron source are presented.
|
|
| 13. |
- Chernitskiy, S. V., et al.
(författare)
-
Neutronic Model of a Stellarator-Mirror Fusion-Fission Hybrid
- 2012
-
Ingår i: PROBL ATOM SCI TECH. - 1562-6016. ; :6, s. 58-60
-
Tidskriftsartikel (refereegranskat)abstract
- The MCNPX numerical code has been used to model a compact concept for a fusion-fission reactor based on a combined stellarator-mirror trap. Calculation results for the radial leakage of neutrons through the mantle surface of the fission reactor are presented.
|
|
| 14. |
- Chernitskiy, S. V., et al.
(författare)
-
Static neutronic calculation of a subcritical transmutation stellarator-mirror fusion-fission hybrid
- 2014
-
Ingår i: Annals of Nuclear Energy. - : Elsevier BV. - 0306-4549 .- 1873-2100. ; 72, s. 413-420
-
Tidskriftsartikel (refereegranskat)abstract
- The MCNPX Monte-Carlo code has been used to model the neutron transport in a sub-critical fast fission reactor driven by a fusion neutron source. A stellarator-mirror device is considered as the fusion neutron source. The principal composition for a fission blanket of a mirror fusion-fission hybrid is devised from the calculations. Heat load on the first wall, the distribution of the neutron fields in the reactor, the neutron spectrum and the distribution of energy release in the blanket are calculated. The possibility of tritium breeding inside the installation in quantities that meet the needs of the fusion neutron source is analyzed. The portion of the plasma column generates fusion neutrons that mainly do not reach the fission reactor core is proposed to be surrounded by a vessel filled with borated water to absorb the flying out neutrons. The flux of the neutrons escaping from the device to surrounding space is also calculated.
|
|
| 15. |
- Cockell, C.S., et al.
(författare)
-
Habitability : a review
- 2016
-
Ingår i: Astrobiology. - : Mary Ann Liebert Inc. - 1531-1074 .- 1557-8070. ; 16:1, s. 89-117
-
Tidskriftsartikel (refereegranskat)abstract
- Habitability is a widely used word in the geoscience, planetary science, and astrobiology literature, but what does it mean? In this review on habitability, we define it as the ability of an environment to support the activity of at least one known organism. We adopt a binary definition of “habitability” and a “habitable environment.” An environment either can or cannot sustain a given organism. However, environments such as entire planets might be capable of supporting more or less species diversity or biomass compared with that of Earth. A clarity in understanding habitability can be obtained by defining instantaneous habitability as the conditions at any given time in a given environment required to sustain the activity of at least one known organism, and continuous planetary habitability as the capacity of a planetary body to sustain habitable conditions on some areas of its surface or within its interior over geological timescales. We also distinguish between surface liquid water worlds (such as Earth) that can sustain liquid water on their surfaces and interior liquid water worlds, such as icy moons and terrestrial-type rocky planets with liquid water only in their interiors. This distinction is important since, while the former can potentially sustain habitable conditions for oxygenic photosynthesis that leads to the rise of atmospheric oxygen and potentially complex multicellularity and intelligence over geological timescales, the latter are unlikely to. Habitable environments do not need to contain life. Although the decoupling of habitability and the presence of life may be rare on Earth, it may be important for understanding the habitability of other planetary bodies
|
|
| 16. |
|
|
| 17. |
|
|
| 18. |
- Douketis, J D, et al.
(författare)
-
Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure : Substudy of the RE-LY trial
- 2015
-
Ingår i: Thrombosis and Haemostasis. - : Georg Thieme Verlag KG. - 0340-6245 .- 2567-689X. ; 113:3, s. 625-632
-
Tidskriftsartikel (refereegranskat)abstract
- In patients with atrial fibrillation (AF) who require interruption of dabigatran or warfarin for an elective surgery/procedure, the risks and benefits of perioperative bridging anticoagulation is uncertain. We accessed the database from RE-LY, a randomised trial comparing dabigatran with warfarin for stroke prevention in AF, to assess the potential benefits and risks of bridging. In patients who had a first interruption of dabigatran or warfarin for an elective surgery/procedure, we compared the risk for major bleeding (MB), stroke or systemic embolism (SSE) and any thromboembolism (TE) in patients who were bridged or not bridged during the period of seven days before until 30 days after surgery/procedure. We used multivariable Cox regression to adjust for potential confounders. Bridging was used more during warfarin interruption than dabigatran interruption (27.5 % vs 15.4 %; p< 0.001). With dabigatran interruption, bridged patients had more MB (6.5 % vs. 1.8 %, P< 0.001) than those not bridged but bridged and not bridged groups did not differ for any TE (1.2 % vs 0.6 %, p=0.16) and SSE (0.5 % vs 0.3 %, p=0.46). With warfarin interruption, bridged patients had more MB (6.8 % vs 1.6 %, p< 0.001) and any TE (1.8 % vs 0.3 %, p=0.007) than those not bridged but bridged and not bridged groups did not differ for SSE (0.5 % vs 0.2 %, p=0.321). In conclusion, in patients who interrupted dabigatran or warfarin for a surgery/procedure in the RE-LY trial, use of bridging anticoagulation appeared to increase the risk for major bleeding irrespective of dabigatran or warfarin interruption.
|
|
| 19. |
- Ezekowitz, Michael D., et al.
(författare)
-
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy)
- 2016
-
Ingår i: Circulation. - 0009-7322 .- 1524-4539. ; 134:8, s. 589-598
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: The RE-LY trial (Randomized Evaluation of Long-Term Anticoagulant Therapy) compared dabigatran 150 and 110 mg twice daily with warfarin in 18 113 patients with atrial fibrillation. Those with prosthetic heart valves, significant mitral stenosis, and valvular heart disease (VHD) requiring intervention were excluded. Others with VHD were included. METHODS: This is a post hoc analysis of the RE-LY trial. RESULTS: There were 3950 patients with any VHD: 3101 had mitral regurgitation, 1179 with tricuspid regurgitation, 817 had aortic regurgitation, 471 with aortic stenosis, and 193 with mild mitral stenosis. At baseline, patients with any VHD had more heart failure, coronary disease, renal impairment, and persistent atrial fibrillation. Patients with any VHD had higher rates of major bleeds (hazard ratio [HR], 1.32; 95% confidence interval [CI], 1.16-1.5) but similar stroke or systemic embolism event rates (HR, 1.09; 95% CI, 0.88-1.33). For patients receiving dabigatran 110 mg, major bleed rates were lower than for patients taking warfarin (HR, 0.73; 95% CI, 0.56-0.95 with VHD; HR, 0.84; 95% CI, 0.71-0.99 without VHD), and major bleed rates for dabigatran 150 mg were similar to those for warfarin in patients with VHD (HR, 0.82; 95% CI, 0.64-1.06) or without VHD (HR, 0.98; 95% CI, 0.83-1.15). For dabigatran 150 mg, stroke/systemic embolic event rates were lower compared with warfarin in those with VHD (HR, 0.59; 95% CI, 0.37-0.93) and those without VHD (HR, 0.67; 95% CI, 0.52-0.86), and stroke/systemic embolic event rates were similar for warfarin and dabigatran 110 mg regardless of the presence of VHD (HR, 0.97; 95% CI, 0.65-1.45; and HR, 0.88; 95% CI, 0.70-1.10). Intracranial bleeds and death rates for dabigatran 150 and 110 mg were lower compared with warfarin independently of the presence of VHD. CONCLUSIONS: The presence of any VHD did not influence the comparison of dabigatran with warfarin.
|
|
| 20. |
|
|
